Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)Jelena Čelutkienė, Alexander R Lyon, Vassilis I. Barberis et al.|European Journal of Heart Failure|2020Cited by 364
Role of Serum Biomarkers in Cancer Patients Receiving Cardiotoxic Cancer Therapies: A Position Statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of CardiologyRadek Pudil, Alexander R Lyon, Christian Mueller et al.|European Journal of Heart Failure|2020Cited by 344
The continuous heart failure spectrum: moving beyond an ejection fraction classificationFilippos Triposkiadis, Gilles W. De Keulenaer, Javed Butler et al.|European Heart Journal|2019Cited by 258
Institutional Profile: Translational Pharmacogenomics at the Icahn School of Medicine at Mount SinaiStuart A. Scott, Eric E. Schadt, Aniwaa Owusu Obeng et al.|Pharmacogenomics|2017Cited by 21
CAVIN1-Mediated hERG Dynamics: A Novel Mechanism Underlying the Interindividual Variability in Drug-Induced Long QTZeina R. Al Sayed, Jean‐Sébastien Hulot|Circulation|2024Cited by 10